126 related articles for article (PubMed ID: 16733671)
21. Characterization of cord blood natural killer and lymphokine activated killer lymphocytes following ex vivo cellular engineering.
Ayello J; van de Ven C; Fortino W; Wade-Harris C; Satwani P; Baxi L; Simpson LL; Sanger W; Pickering D; Kurtzberg J; Cairo MS
Biol Blood Marrow Transplant; 2006 Jun; 12(6):608-22. PubMed ID: 16737934
[TBL] [Abstract][Full Text] [Related]
22. Collagen-based matrices improve the delivery of transplanted circulating progenitor cells: development and demonstration by ex vivo radionuclide cell labeling and in vivo tracking with positron-emission tomography.
Zhang Y; Thorn S; DaSilva JN; Lamoureux M; DeKemp RA; Beanlands RS; Ruel M; Suuronen EJ
Circ Cardiovasc Imaging; 2008 Nov; 1(3):197-204. PubMed ID: 19808543
[TBL] [Abstract][Full Text] [Related]
23. IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial.
Burns LJ; Weisdorf DJ; DeFor TE; Vesole DH; Repka TL; Blazar BR; Burger SR; Panoskaltsis-Mortari A; Keever-Taylor CA; Zhang MJ; Miller JS
Bone Marrow Transplant; 2003 Jul; 32(2):177-86. PubMed ID: 12838283
[TBL] [Abstract][Full Text] [Related]
24. Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy.
Ayello J; van de Ven C; Cairo E; Hochberg J; Baxi L; Satwani P; Cairo MS
Exp Hematol; 2009 Oct; 37(10):1216-29. PubMed ID: 19638292
[TBL] [Abstract][Full Text] [Related]
25. Therapy of recurrent high-grade gliomas with surgery, autologous mitogen-activated IL-2-stimulated (MAK) killer lymphocytes, and rIL-2: II. Correlation of survival with MAK cell tumor necrosis factor production in vitro.
Jeffes EW; Beamer YB; Jacques S; Coss JS; Nep RL; Beckman M; Yamamoto RS; Granger G
Lymphokine Cytokine Res; 1991 Apr; 10(1-2):89-94. PubMed ID: 1873360
[TBL] [Abstract][Full Text] [Related]
26. Induction of human tumor-associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer.
Bellone S; Anfossi S; O'Brien TJ; Cannon MJ; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Cancer; 2009 Feb; 115(4):800-11. PubMed ID: 19117353
[TBL] [Abstract][Full Text] [Related]
27. [Effect of lymphokine activated killer from umbilical blood on human ovarian cancer in nude mouse models].
He YD; Peng ZL; Liu SL; Wang H; Pan XL
Sichuan Da Xue Xue Bao Yi Xue Ban; 2007 Sep; 38(5):810-2. PubMed ID: 17953364
[TBL] [Abstract][Full Text] [Related]
28. Visualization of effective tumor targeting by CD8+ natural killer T cells redirected with bispecific antibody F(ab')(2)HER2xCD3.
Scheffold C; Kornacker M; Scheffold YC; Contag CH; Negrin RS
Cancer Res; 2002 Oct; 62(20):5785-91. PubMed ID: 12384539
[TBL] [Abstract][Full Text] [Related]
29. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
Rosenblum MG; Verschraegen CF; Murray JL; Kudelka AP; Gano J; Cheung L; Kavanagh JJ
Clin Cancer Res; 1999 May; 5(5):953-61. PubMed ID: 10353726
[TBL] [Abstract][Full Text] [Related]
30. [Monoclonal anti-idiotype antibodies in immunotherapy of ovarian carcinoma (MAb ACA125) and breast carcinoma (MAb ACA14C5)].
Wagner U; Köhler S; Prietl G; Giffels P; Schmidt-Nicolai S; Schlebusch H; Grünn U; Bender H; Biersack HJ; De Potter C; Krebs D; Wallwiener D
Zentralbl Gynakol; 1999; 121(4):190-5. PubMed ID: 10355096
[TBL] [Abstract][Full Text] [Related]
31. Production of macrophage-activated killer cells for targeting of glioblastoma cells with bispecific antibody to FcgammaRI and the epidermal growth factor receptor.
Wallace PK; Romet-Lemonne JL; Chokri M; Kasper LH; Fanger MW; Fadul CE
Cancer Immunol Immunother; 2000 Nov; 49(9):493-503. PubMed ID: 11092616
[TBL] [Abstract][Full Text] [Related]
32. Adoptive immunotherapy of ovarian carcinoma.
de Gramont A; Gangji D; Louvet C; Garcia ML; Tardy D; Romet-Lemonne JL
Gynecol Oncol; 2002 Jul; 86(1):102-3. PubMed ID: 12079309
[No Abstract] [Full Text] [Related]
33. Adoptive immunotherapy with bispecific antibodies: targeting through macrophages.
Chokri M; Girard A; Borrelly MC; Oleron C; Romet-Lemonne JL; Bartholeyns J
Res Immunol; 1992 Jan; 143(1):95-9. PubMed ID: 1533049
[TBL] [Abstract][Full Text] [Related]
34. Increased systemic, but not regional, neopterin production following intraperitoneal administration of interleukin-2 and lack of effect of pterins upon the lymphokine-activated killer cell phenomenon.
Roberts JD; Bigelow JC; Moore AL; Belinson JL; Stewart JA; Hacker MP
J Immunother Emphasis Tumor Immunol; 1994 Jan; 15(1):53-8. PubMed ID: 8110731
[TBL] [Abstract][Full Text] [Related]
35. Monocyte/macrophages as effector cells in cancer immunotherapy.
Oberling F
Transfus Sci; 1997 Jun; 18(2):243-50. PubMed ID: 10174690
[TBL] [Abstract][Full Text] [Related]
36. Allogenic natural killer cell immunotherapy of sizeable ovarian cancer: A case report.
Xie S; Chen J; Zhang M; Wu Z
Mol Clin Oncol; 2017 Jun; 6(6):903-906. PubMed ID: 28588787
[TBL] [Abstract][Full Text] [Related]
37. An indium-111-labelled membrane-targeted peptide for cell tracking with radionuclide imaging.
Pruller J; Pham TT; Blower JE; Charoenphun P; Volpe A; Sunassee K; Mullen GED; Blower PJ; Smith RAG; Ma MT
RSC Chem Biol; 2023 Jan; 4(1):65-73. PubMed ID: 36685254
[TBL] [Abstract][Full Text] [Related]
38. Modifying effects of maharishi amrit kalash 4 and 5 on phagocytic and digestive functions of macrophages in male icr mice.
Sugiura H; Inaba R; Iwata H; Nishida H; Tanaka T
Environ Health Prev Med; 1998 Apr; 3(1):50-4. PubMed ID: 21432508
[TBL] [Abstract][Full Text] [Related]
39. [Immunotherapy of metastasizing malignant tumors].
AUDIER AG
Med Nov; 1959 Oct; 40():1860-4. PubMed ID: 13795043
[No Abstract] [Full Text] [Related]
40. Unproven methods of cancer treatment. Rand coupled fortified antigen (RCFA) and delayed double diffusion (3-D) test.
CA Cancer J Clin; 1969; 19(4):251-4. PubMed ID: 4979763
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
